Arava and Skin hyperpigmentation - a phase IV clinical study of FDA data

Summary:

Skin hyperpigmentation is reported as a side effect among people who take Arava (leflunomide), especially for people who are female, 50-59 old, also take Plaquenil, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Skin hyperpigmentation when taking Arava. It is created by eHealthMe based on reports of 75,674 people who have side effects when taking Arava from the FDA, and is updated regularly.

What is Arava?

Arava has active ingredients of leflunomide. It is often used in rheumatoid arthritis. eHealthMe is studying from 76,040 Arava users. Check the latest studies of Arava.

What is Skin hyperpigmentation?

Skin hyperpigmentation (disorders affect the colour of your skin) is found to be associated with 646 drugs and 811 conditions by eHealthMe. Check the latest studies of Skin hyperpigmentation.

On Jul, 14, 2026

75,674 people reported to have side effects when taking Arava.
Among them, 30 people (0.04%) have Skin hyperpigmentation.

Could Arava cause Skin hyperpigmentation?

Among these 30 people:

What is the gender of people who have Skin hyperpigmentation when taking Arava? *

female: 100 %
male: 0.0 %

What is the age of people who have Skin hyperpigmentation when taking Arava? *

What are other drugs people take besides Arava? *

What are other side effects people have besides Skin hyperpigmentation? *

Dry Skin: 10 people, 33.33%
Mobility Decreased (ability to move is reduced): 10 people, 33.33%
Pain: 9 people, 30.00%
White Blood Cell Count Decreased: 8 people, 26.67%
Extremity Contracture (permanent shortening of a muscle or joint of arms and legs): 8 people, 26.67%
Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 8 people, 26.67%
Oedema (fluid collection in tissue): 8 people, 26.67%
Common Peroneal Nerve Dysfunction (dysfunction of nerve controlling movement and sensation to the lower leg, foot and toes): 8 people, 26.67%
Subcutaneous Nodule: 8 people, 26.67%
Peripheral Ischaemia (impaired circulation to an extremity): 8 people, 26.67%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 8 people, 26.67%
Nuclear Magnetic Resonance Imaging Abdominal: 2 people, 6.67%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 2 people, 6.67%
Juvenile Arthritis (arthritis-related condition that develops in children or teenagers): 2 people, 6.67%
Type 2 Diabetes: 1 person, 3.33%
Nausea (feeling of having an urge to vomit): 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Arava and have Skin hyperpigmentation?

- Check whether Skin hyperpigmentation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Arava:

Arava (76,040 reports)

Browse all side effects of Arava:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (646 drugs)

Browse all the conditions that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (811 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on leflunomide (the active ingredients of Arava) and Arava (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.